BEAM-201
- Generic Name
- BEAM-201
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Phase 1
Active, not recruiting
- Conditions
- Lymphoblastic LeukemiaLymphoblastic LymphomaT-Cell Lymphoblastic Leukemia/Lymphoma
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Beam Therapeutics Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05885464
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath